Avid Bioservices, Argonaut Enter Manufacturing Services Pact

Avid Bioservices, Inc., a biologics CDMO, and Argonaut Manufacturing Services, a cGMP contract manufacturing organization (CMO) have entered a co-marketing agreement to provide an integrated manufacturing solution including process development, drug substance manufacturing, and drug product manufacturing. The companies will offer Avid’s upstream and downstream process development and drug substance manufacturing services in tandem with Argonaut’s parenteral drug product fill-finish services, to support the efficient delivery of CGMP parenteral drug products for use in clinical studies.

“As we continue to expand our biologics manufacturing client base, Avid is leveraging a strategy of aligning with industry leaders that are capable of offering critical complementary services to our customers,” said Timothy Compton, chief commercial officer of Avid. “In entering this agreement with Argonaut, we are offering our clients access to CGMP qualified parenteral fill-finish services within an hour’s drive from our drug substance development and manufacturing facilities. This will provide a drug substance-to-drug product solution for our clients as they move their novel, high-value biologic therapeutics through clinical development.”

“Argonaut has always endeavored to provide our clients with a trusted network of complementary service providers through our Ecosystem Partnership program,” said Eric Blair, chief commercial officer of Argonaut. “Our partnership with Avid unlocks key process development and drug substance manufacturing capabilities for our clients, which are a perfect fit with our state-of-the-art aseptic fill-finish offering. Together, Avid and Argonaut offer a complete solution for customers that are bringing biologic therapeutics to market.”